Abstract:Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the "caffeine-like effects" of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki < 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg–1, i.p. rats). Compound 12 (2 mg kg–1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00914?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914</a>.Spectroscopic and analytical data; general LC–MS analytics; general synthesis, fluorescence characterization of compound 12 (ST-1992); drug-likeness of synthetized MTLs 4 (ST-2001) and 12 (ST-1992); cell viability of human neuroblastoma cells treated with MTLs 2, 4 (ST-2001) , and 6; in vitro radioligand binding experiments for compounds 4 (ST-2001) and 12 (ST-1992); in vivo studies of compound 4 (ST-2001); additional in vivo evaluation of compound 12 (ST-1992); and experimental part with references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">CSV</a>)Modeling structure of A2AR with preladenant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">PDB</a>)Modeling structure of A2AR with ST-1992 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">PDB</a>)This article has not yet been cited by other publications.

2,6-Diaryl-4-acylaminopyrimidines As Potent and Selective Adenosine A2A Antagonists with Improved Solubility and Metabolic Stability

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Discovery of Pyridinone Derivatives As Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Synthesis and Pharmacological Characterization of 4-Substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: Identification of New Potent and Selective Metabotropic Glutamate 2/3 Receptor Agonists.

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Adenosine A 2A R/A 1 R Antagonists Enabling Additional H 3 R Antagonism for the Treatment of Parkinson’s Disease

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

Synthesis and Properties of a New Water-Soluble Prodrug of the Adenosine A2A Receptor Antagonist MSX-2

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8h)-one Derivatives As Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile

Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-n-(adamant-2-yl) Acetamide 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors.

Subtle Structural Changes Across the Boundary Between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives.

Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.

Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A 2A Adenosine Receptor Antagonists: Exploring the Roles of Ribose at Adenosine Receptors

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening